loading page

Effect of gut flora mediated-bile acid metabolism on intestinal immune microenvironment
  • +7
  • Yan Zhang,
  • Xueyan Gao,
  • Yudi Feng,
  • Yang Liu,
  • Shuochen Gao,
  • Liping Pei,
  • Wenkang Wang,
  • Zhenqiang Sun,
  • Lin Liu,
  • Chengzeng Wang
Yan Zhang
The First Affiliated Hospital of Zhengzhou University

Corresponding Author:[email protected]

Author Profile
Xueyan Gao
The First Affiliated Hospital of Zhengzhou University
Author Profile
Yudi Feng
The First Affiliated Hospital of Zhengzhou University
Author Profile
Yang Liu
Henan Cancer Hospital
Author Profile
Shuochen Gao
The First Affiliated Hospital of Zhengzhou University
Author Profile
Liping Pei
The First Affiliated Hospital of Zhengzhou University
Author Profile
Wenkang Wang
The First Affiliated Hospital of Zhengzhou University
Author Profile
Zhenqiang Sun
The First Affiliated Hospital of Zhengzhou University
Author Profile
Lin Liu
The First Affiliated Hospital of Zhengzhou University
Author Profile
Chengzeng Wang
The First Affiliated Hospital of Zhengzhou University
Author Profile

Abstract

According to reports, gut microbiota and metabolites regulate intestinal immune microenvironment. In recent years, an increasing number of studies reported that bile acids (BAs) of intestinal flora origin affects T helper cells and Treg cells. Th17 cells play a pro-inflammatory role and Treg cells usually act an immunosuppressive role. In this review, we emphatically summarized the influence and corresponding mechanism of different configurations of the LCA and DCA on intestinal Th17 cells, Treg cells and intestinal immune microenvironment. The regulation of BAs receptors G protein-coupled bile acid receptor 1 (GPBAR1/TGR5) and farnesoid X receptor (FXR) on immune cells and intestinal environment are elaborated. Furthermore, the potential clinical applications above were also concluded in three aspects. These above will help researchers better understand the effects of gut flora on the intestinal immune microenvironment via BAs and contribute to the development of new targeted drugs.
07 Mar 2023Submitted to Immunology
24 Mar 2023Reviewer(s) Assigned
17 Apr 2023Review(s) Completed, Editorial Evaluation Pending
28 Apr 2023Editorial Decision: Revise Minor
22 May 20231st Revision Received
23 May 2023Review(s) Completed, Editorial Evaluation Pending
23 May 2023Submission Checks Completed
23 May 2023Assigned to Editor
26 May 2023Reviewer(s) Assigned
29 May 2023Editorial Decision: Accept